Katherine A. Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine A. Davies has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Stephen R. Welch
Centers for Disease Control and Prevention
10 shared publications - Christina F. Spiropoulou
Centers for Disease Control and Prevention
9 shared publications - Jessica R. Spengler
Centers for Disease Control and Prevention
9 shared publications - Teresa E. Sorvillo
Centers for Disease Control and Prevention
7 shared publications - JoAnn D. Coleman-McCray
Centers for Disease Control and Prevention
6 shared publications - Joel M. Montgomery
Centers for Disease Control and Prevention
5 shared publications
Latest Publications
- 17 November 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Viral persistence and post-acute outcomes following high-consequence negative-sense RNA virus infections
- 17 November 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Viral persistence and post-acute outcomes following high-consequence negative-sense RNA virus infections
- 5 August 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Pathogenicity and virulence of Crimean-Congo hemorrhagic fever virus: From enzootic maintenance to severe human disease
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne illness caused by infection with the CCHF virus (CCHFV; Orthonairovirus haemorrhagiae), with clinical manifestations ranging from mild disease...
- 5 August 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1)
Pathogenicity and virulence of Crimean-Congo hemorrhagic fever virus: From enzootic maintenance to severe human disease
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne illness caused by infection with the CCHF virus (CCHFV; Orthonairovirus haemorrhagiae), with clinical manifestations ranging from mild disease...
- 24 July 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1)
Longitudinal in vivo imaging reveals asynchronous, incomplete Nipah virus clearance with prolonged focal CNS involvement in IFNAR −/− mice
Nipah virus (NiV; Paramyxoviridae, Henipavirus) causes a broad clinical spectrum ranging from asymptomatic infection to severe respiratory and neurological illness [1]. Two genetically distinct str...
- 24 July 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1)
Longitudinal in vivo imaging reveals asynchronous, incomplete Nipah virus clearance with prolonged focal CNS involvement in IFNAR −/− mice
Nipah virus (NiV; Paramyxoviridae, Henipavirus) causes a broad clinical spectrum ranging from asymptomatic infection to severe respiratory and neurological illness [1]. Two genetically distinct str...
- 11 March 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (3) , e0170925
Monoclonal IgM antibodies mediate potent complement neutralization by targeting cell-derived epitopes on enveloped viruses
When studying virus neutralization by specific antibodies of the adaptive immune response, serum heat treatment is a standard procedure done to eliminate any non-specific effects by the complement system. Although non-specific, innate immune responses such as these may be relevant in determining infection outcome. We observed extensive variation between negative control donors in their ability to neutralize Ebola virus and other enveloped viruses in the presence of complement. The effect was mediated by the classical pathway of complement activation, with serum IgM the main initiator in a manner that depended on the cell line that produced the virus. To identify the epitope, three monoclonal IgM antibodies were isolated after a neutralization screen and probed against arrayed glycans. The antibodies were found to bind ganglioside GM2, and the test virus was rendered refractory to anti-GM2 neutralization when propagated in the presence of an inhibitor of ganglioside synthesis. Gangliosides and other host membrane moieties are known to be carried by viruses and to aid entry to cells. The findings here suggest that under specific circumstances, such moieties incorporated in lipid envelopes of viruses can be recognized by potently neutralizing IgM antibodies present in the serum of immunologically naïve individuals. IMPORTANCE: Neutralization, that is, the ability to block infection in cell culture, remains the primary functional attribute of therapeutic antibodies and humoral immune responses against viruses. Beyond direct effects—such as preventing virus attachment to the cell—virus inactivation by antibody-mediated complement deposition or lysis is often considered a type of neutralization. Viral envelope glycoproteins are the main targets of neutralizing antibodies. However, because viruses obtain their membranes from cells in which they replicate, the membranes are known to contain cell-derived markers in addition to virally encoded proteins. Having observed marked individual variance in naïve serum donors’ ability to neutralize Ebola virus and other enveloped viruses, we sought to understand the mechanism. Three IgM monoclonals targeting a cell-derived epitope were isolated. The findings expand on the importance of cellular factors exposed on the virion membrane and suggest that they may be targets of potent antibody-mediated immune monitoring.
- 11 March 2026
- Published by American Society for Microbiology in mBio
- Vol. 17 (3) , e0170925
Monoclonal IgM antibodies mediate potent complement neutralization by targeting cell-derived epitopes on enveloped viruses
When studying virus neutralization by specific antibodies of the adaptive immune response, serum heat treatment is a standard procedure done to eliminate any non-specific effects by the complement system. Although non-specific, innate immune responses such as these may be relevant in determining infection outcome. We observed extensive variation between negative control donors in their ability to neutralize Ebola virus and other enveloped viruses in the presence of complement. The effect was mediated by the classical pathway of complement activation, with serum IgM the main initiator in a manner that depended on the cell line that produced the virus. To identify the epitope, three monoclonal IgM antibodies were isolated after a neutralization screen and probed against arrayed glycans. The antibodies were found to bind ganglioside GM2, and the test virus was rendered refractory to anti-GM2 neutralization when propagated in the presence of an inhibitor of ganglioside synthesis. Gangliosides and other host membrane moieties are known to be carried by viruses and to aid entry to cells. The findings here suggest that under specific circumstances, such moieties incorporated in lipid envelopes of viruses can be recognized by potently neutralizing IgM antibodies present in the serum of immunologically naïve individuals. IMPORTANCE: Neutralization, that is, the ability to block infection in cell culture, remains the primary functional attribute of therapeutic antibodies and humoral immune responses against viruses. Beyond direct effects—such as preventing virus attachment to the cell—virus inactivation by antibody-mediated complement deposition or lysis is often considered a type of neutralization. Viral envelope glycoproteins are the main targets of neutralizing antibodies. However, because viruses obtain their membranes from cells in which they replicate, the membranes are known to contain cell-derived markers in addition to virally encoded proteins. Having observed marked individual variance in naïve serum donors’ ability to neutralize Ebola virus and other enveloped viruses, we sought to understand the mechanism. Three IgM monoclonals targeting a cell-derived epitope were isolated. The findings expand on the importance of cellular factors exposed on the virion membrane and suggest that they may be targets of potent antibody-mediated immune monitoring.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (5) , e1267-e1272
Characterization of Mouse-Adapted Marburg and Ravn Viruses in Inbred BALB/c and Outbred CD-1 Mice
Marburgviruses cause severe hemorrhagic disease in humans, yet characterization of rodent models for pathogenesis and medical countermeasure development remains limited. Here, we investigated clinical course, blood chemistry, viral dissemination, and mucosal viral detection in inbred BALB/c and outbred CD-1 mice infected with mouse-adapted (MA)-Marburg virus (MARV)/Angola or MA-Ravn virus (RAVV) to further mouse model development. Regardless of virus or mouse strain, infection resulted in widespread viral dissemination in animals sampled up to 5 days post-infection. However, in animals followed to study end, MA-MARV/Angola caused severe disease and lethality in both mouse strains, whereas MA-RAVV caused mild or asymptomatic infection.
- 8 January 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (5) , e1267-e1272
Open AccessCharacterization of Mouse-Adapted Marburg and Ravn Viruses in Inbred BALB/c and Outbred CD-1 Mice
Marburgviruses cause severe hemorrhagic disease in humans, yet characterization of rodent models for pathogenesis and medical countermeasure development remains limited. Here, we investigated clinical course, blood chemistry, viral dissemination, and mucosal viral detection in inbred BALB/c and outbred CD-1 mice infected with mouse-adapted (MA)-Marburg virus (MARV)/Angola or MA-Ravn virus (RAVV) to further mouse model development. Regardless of virus or mouse strain, infection resulted in widespread viral dissemination in animals sampled up to 5 days post-infection. However, in animals followed to study end, MA-MARV/Angola caused severe disease and lethality in both mouse strains, whereas MA-RAVV caused mild or asymptomatic infection.
- 28 December 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2595795
Crimean-Congo hemorrhagic fever virus localization and shedding in the reproductive tract of lethal and survivor mouse models
Hemorrhagic fever viruses have been shown to localize to immune-privileged sites, including the reproductive tract, raising important questions about long-term persistence and the potential for sexual transmission. Anecdotal evidence of sexual transmission of Crimean-Congo hemorrhagic fever virus (CCHFV) has been reported, and in vivo studies suggest that CCHFV can localize to reproductive tissues; however, to date, this phenomenon has not been explicitly investigated. We evaluated histopathology and viral loads (viral RNA, viral antigen, and infectious viral titers) in reproductive tissues obtained from lethal and survivor mouse models of CCHFV during acute and convalescent phases of infection. Viral loads in urogenital swabs were also evaluated to assess the potential for virus transmission. Although no evidence of long-term persistence was observed in the survivor model of CCHF, our data indicate a potential for sexual transmission during acute infection, even in cases of mild disease, as infectious virus was isolated from urogenital swabs. These data support the importance of sampling human patients to better define the risk of sexual transmission and potential viral persistence in reproductive tissues during and after recovery from CCHF.
- 28 December 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2595795
Crimean-Congo hemorrhagic fever virus localization and shedding in the reproductive tract of lethal and survivor mouse models
Hemorrhagic fever viruses have been shown to localize to immune-privileged sites, including the reproductive tract, raising important questions about long-term persistence and the potential for sexual transmission. Anecdotal evidence of sexual transmission of Crimean-Congo hemorrhagic fever virus (CCHFV) has been reported, and in vivo studies suggest that CCHFV can localize to reproductive tissues; however, to date, this phenomenon has not been explicitly investigated. We evaluated histopathology and viral loads (viral RNA, viral antigen, and infectious viral titers) in reproductive tissues obtained from lethal and survivor mouse models of CCHFV during acute and convalescent phases of infection. Viral loads in urogenital swabs were also evaluated to assess the potential for virus transmission. Although no evidence of long-term persistence was observed in the survivor model of CCHF, our data indicate a potential for sexual transmission during acute infection, even in cases of mild disease, as infectious virus was isolated from urogenital swabs. These data support the importance of sampling human patients to better define the risk of sexual transmission and potential viral persistence in reproductive tissues during and after recovery from CCHF.
- Open Access
- 29 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e441-e453
Natural History of Nipah Virus in Hamsters: Strain, Route, and Sex-Associated Variability Characterized Using Large Datasets to Inform Pre-Clinical Study Design
Nipah virus (NiV) comprises two strains, Malaysia and Bangladesh, associated with severe respiratory and/or neurological disease in humans. Experimentally infected Syrian hamsters demonstrate the full spectrum of clinical signs reported in humans, serving as valuable pre-clinical screening models for NiV disease. Medical countermeasure development relies on well-characterized disease models to understand disease progression, guiding pre-clinical and clinical trial design. Variability in NiV-disease presentation and outcome necessitates large group sizes in animal model natural history studies. To advance the use of hamsters in NiV pre-clinical studies, we analyzed in-house data from 19 independent studies comprising over 500 hamsters intranasally or intraperitoneally infected with NiV-Malaysia or NiV-Bangladesh. We demonstrate strain- and route-associated differences in clinical course, lethality, and viral loads, presenting cohort and individual data. These analyses provide key data to guide experimental design for pathogenesis, pathophysiology, and medical countermeasure studies.
- 29 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e441-e453
Open AccessNatural History of Nipah Virus in Hamsters: Strain, Route, and Sex-Associated Variability Characterized Using Large Datasets to Inform Pre-Clinical Study Design
Nipah virus (NiV) comprises two strains, Malaysia and Bangladesh, associated with severe respiratory and/or neurological disease in humans. Experimentally infected Syrian hamsters demonstrate the full spectrum of clinical signs reported in humans, serving as valuable pre-clinical screening models for NiV disease. Medical countermeasure development relies on well-characterized disease models to understand disease progression, guiding pre-clinical and clinical trial design. Variability in NiV-disease presentation and outcome necessitates large group sizes in animal model natural history studies. To advance the use of hamsters in NiV pre-clinical studies, we analyzed in-house data from 19 independent studies comprising over 500 hamsters intranasally or intraperitoneally infected with NiV-Malaysia or NiV-Bangladesh. We demonstrate strain- and route-associated differences in clinical course, lethality, and viral loads, presenting cohort and individual data. These analyses provide key data to guide experimental design for pathogenesis, pathophysiology, and medical countermeasure studies.
- 20 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (774) , eado7034
Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4′-fluorouridine (4′-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4′-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4′-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4′-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4′-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4′-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.
- 20 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (774) , eado7034
Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4′-fluorouridine (4′-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4′-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4′-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4′-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4′-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4′-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.
- Open Access
- 19 November 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2427782
Inflammation associated with monocyte/macrophage activation and recruitment corresponds with lethal outcome in a mouse model of Crimean-Congo haemorrhagic fever
Crimean-Congo haemorrhagic fever virus (CCHFV) causes human disease ranging from subclinical to a fatal haemorrhagic syndrome. Determinants of CCHF pathogenesis are largely unknown and animal models that recapitulate human disease are limited. A recently described mouse model uses a monoclonal antibody (mAb 5A3) targeting the interferon (IFN) alpha/beta receptor to suppress type I IFN responses, making animals transiently susceptible to infection. To advance utility of this model, we investigated effects of challenge route, timing of 5A3 delivery, mouse sex and age, and virus strain on clinical course and outcome. C57BL/6J mice received mAb 5A3 -1, 0, or -1/+1 days post-infection (dpi). Subsets were challenged with CCHFV strain Turkey04 or IbAr10200 subcutaneously or intraperitoneally, and serially euthanized 3- and 7-dpi, when meeting euthanasia criteria or at study completion (14 dpi). CCHFV-IbAr10200-infected mice almost uniformly succumbed to infection, whereas CCHFV-Turkey04-infected mice transiently lost weight but survived. These results were consistent regardless of mAb timing or route of challenge. Viral replication and dissemination were comparable between the two strains at 3 dpi. However, in the plasma and livers of non-survivors, expression of proinflammatory cytokines/chemokines that correspond with macrophage activation and recruitment were significantly elevated. Lethal disease was also associated with elevated levels of macrophage activation marker CD163 in plasma. Further, mouse macrophages were more permissive to IbAr1200 infection in vitro, suggesting tropism for these cells may influence pathogenesis. Our data suggest that early inflammation may be a critical determinant of CCHF outcome and therapeutics to control inflammation may be worthwhile targets for future investigation.
- 19 November 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2427782
Open AccessInflammation associated with monocyte/macrophage activation and recruitment corresponds with lethal outcome in a mouse model of Crimean-Congo haemorrhagic fever
Crimean-Congo haemorrhagic fever virus (CCHFV) causes human disease ranging from subclinical to a fatal haemorrhagic syndrome. Determinants of CCHF pathogenesis are largely unknown and animal models that recapitulate human disease are limited. A recently described mouse model uses a monoclonal antibody (mAb 5A3) targeting the interferon (IFN) alpha/beta receptor to suppress type I IFN responses, making animals transiently susceptible to infection. To advance utility of this model, we investigated effects of challenge route, timing of 5A3 delivery, mouse sex and age, and virus strain on clinical course and outcome. C57BL/6J mice received mAb 5A3 -1, 0, or -1/+1 days post-infection (dpi). Subsets were challenged with CCHFV strain Turkey04 or IbAr10200 subcutaneously or intraperitoneally, and serially euthanized 3- and 7-dpi, when meeting euthanasia criteria or at study completion (14 dpi). CCHFV-IbAr10200-infected mice almost uniformly succumbed to infection, whereas CCHFV-Turkey04-infected mice transiently lost weight but survived. These results were consistent regardless of mAb timing or route of challenge. Viral replication and dissemination were comparable between the two strains at 3 dpi. However, in the plasma and livers of non-survivors, expression of proinflammatory cytokines/chemokines that correspond with macrophage activation and recruitment were significantly elevated. Lethal disease was also associated with elevated levels of macrophage activation marker CD163 in plasma. Further, mouse macrophages were more permissive to IbAr1200 infection in vitro, suggesting tropism for these cells may influence pathogenesis. Our data suggest that early inflammation may be a critical determinant of CCHF outcome and therapeutics to control inflammation may be worthwhile targets for future investigation.
- Open Access
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (31) , eadh4057
Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination
Nipah virus (NiV) causes a highly lethal disease in humans who present with acute respiratory or neurological signs. No vaccines against NiV have been approved to date. Here, we report on the clinical impact of a novel NiV-derived nonspreading replicon particle lacking the fusion (F) protein gene (NiVΔF) as a vaccine in three small animal models of disease. A broad antibody response was detected that included immunoglobulin G (IgG) and IgA subtypes with demonstrable Fc-mediated effector function targeting multiple viral antigens. Single-dose intranasal vaccination up to 3 days before challenge prevented clinical signs and reduced virus levels in hamsters and immunocompromised mice; decreases were seen in tissues and mucosal secretions, critically decreasing potential for virus transmission. This virus replicon particle system provides a vital tool to the field and demonstrates utility as a highly efficacious and safe vaccine candidate that can be administered parenterally or mucosally to protect against lethal Nipah disease.
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (31) , eadh4057
Open AccessSingle-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination
Nipah virus (NiV) causes a highly lethal disease in humans who present with acute respiratory or neurological signs. No vaccines against NiV have been approved to date. Here, we report on the clinical impact of a novel NiV-derived nonspreading replicon particle lacking the fusion (F) protein gene (NiVΔF) as a vaccine in three small animal models of disease. A broad antibody response was detected that included immunoglobulin G (IgG) and IgA subtypes with demonstrable Fc-mediated effector function targeting multiple viral antigens. Single-dose intranasal vaccination up to 3 days before challenge prevented clinical signs and reduced virus levels in hamsters and immunocompromised mice; decreases were seen in tissues and mucosal secretions, critically decreasing potential for virus transmission. This virus replicon particle system provides a vital tool to the field and demonstrates utility as a highly efficacious and safe vaccine candidate that can be administered parenterally or mucosally to protect against lethal Nipah disease.